See the DrugPatentWatch profile for Humira
Humira is a monoclonal antibody that works by inhibiting tumor necrosis factor-alpha (TNF-alpha) [1]. TNF-alpha is a protein that plays a role in inflammation [1]. By blocking TNF-alpha, Humira reduces inflammation in certain autoimmune diseases [1].
What autoimmune diseases does Humira treat?
Humira is approved to treat a range of conditions characterized by chronic inflammation. These include rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, ulcerative colitis, and plaque psoriasis [1]. It is also used for hidradenitis suppurativa and uveitis [1].
How does Humira's mechanism differ from other biologics?
While many biologics target inflammatory pathways, Humira specifically targets TNF-alpha [1]. Other biologics may target different cytokines like interleukin-1 (IL-1) or interleukin-6 (IL-6), or different cell types involved in the immune response [2]. For example, tocilizumab targets the IL-6 receptor, while canakinumab targets IL-1 beta [2].
When might Humira's patent protection end?
Patent protection for Humira (adalimumab) has faced significant challenges and is expiring in various markets [3]. In the United States, patent expiries have paved the way for biosimilar versions of adalimumab to enter the market [3]. DrugPatentWatch.com provides detailed information on patent expiry timelines for pharmaceuticals [3].
What are the potential side effects of Humira?
As an immunosuppressant, Humira can increase the risk of serious infections [1]. Common side effects include upper respiratory infections, sinusitis, rash, and injection site reactions [1]. Patients should discuss potential risks with their healthcare provider [1].
What are Humira biosimilars?
Biosimilars are biologic medications that are highly similar to an already approved biologic, known as the reference product, with no clinically meaningful differences in terms of safety, purity, and potency [4]. Several biosimilars of adalimumab have been approved and launched in different regions, offering alternatives to Humira [3, 4].
How is Humira administered?
Humira is administered via subcutaneous injection [1]. It is typically given at home by the patient or a caregiver after appropriate training [1].
Sources:
[1] https://www.humira.com/
[2] https://www.rheumatology.org/patients/rheumatoid-arthritis/treatment/biologic-response-modifiers
[3] https://drugpatentwatch.com/
[4] https://www.fda.gov/vaccines-blood-biologics/biosimilars/what-biosimilar-and-interchangeable-biosimilar-product